Mouse BV2 nuclear Nrf2 accumulation: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

MK2206 attenuated shikimic-acid-associated Nrf2 accumulation.
MK2206 → Mouse BV2 nuclear Nrf2 accumulation source_derived_draftungraded
Experimental context and source evidence
evidence_access
Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.
experimental_condition
Shikimic acid without MK2206 present · Shikimic acid Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_condition
Shikimic acid without MK2206 pretreatment · MK2206 Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "MK2206 pretreatment with shikimic acid", "comparator": "Shikimic acid without MK2206", "endpoint": "MK2206 attenuated shikimic-acid-associated Nrf2 accumulation.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "mk2206", "state": "pretreatment"}, {"entity_slug": "shikimic-acid", "state": "present"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse BV2; MK2206 10 µM for 4 h before pathway assay.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Pharmacological pathway perturbation; not proof of direct SA–AKT binding or perfect inhibitor specificity.
plain_language
MK2206 attenuated shikimic-acid-associated Nrf2 accumulation.
primary_references
Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced in vitro and in vivo model. | 2023 | DOI 10.3389/fphar.2023.1265571 | PMID 38026972 | https://pubmed.ncbi.nlm.nih.gov/38026972/ | https://doi.org/10.3389/fphar.2023.1265571 | https://pmc.ncbi.nlm.nih.gov/articles/PMC10652795/
source_locator
Reviewed reference lines 61-61; exact primary location described in quoted passage where extracted.
Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026) · lines 61–61
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse BV2; MK2206 10 µM for 4 h before pathway assay. · source_derived_draft · unverified_draft
**AKT and Nrf2 involvement does not identify the binding target.** BV2 experiments recorded increased AKT phosphorylation and nuclear Nrf2. MK2206 pretreatment attenuated Nrf2 activation and partially reversed redox/nitrite responses. A reagent labeled RA also attenuated the Nrf2 response; its identity and selectivity are not independently resolved here, so no vitamin-A or retinoic-acid interaction is created from that abbreviation. Pharmacological perturbation supports pathway involvement while leaving the initiating target and off-target alternatives open. [Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced in vitro and in vivo model.](https://pubmed.ncbi.nlm.nih.gov/38026972/)
Complete structured claim and evidence
Shikimic acid increased nuclear Nrf2 accumulation in BV2 cells.
Shikimic acid → Mouse BV2 nuclear Nrf2 accumulation source_derived_draftungraded
Experimental context and source evidence
evidence_access
Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.
experimental_contrast
{"intervention": "Shikimic acid", "comparator": "Matched cells without SA", "endpoint": "Shikimic acid increased nuclear Nrf2 accumulation in BV2 cells.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse BV2 signaling time-course.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Pathway response is not direct ligand binding or clinical efficacy.
plain_language
Shikimic acid increased nuclear Nrf2 accumulation in BV2 cells.
primary_references
Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced in vitro and in vivo model. | 2023 | DOI 10.3389/fphar.2023.1265571 | PMID 38026972 | https://pubmed.ncbi.nlm.nih.gov/38026972/ | https://doi.org/10.3389/fphar.2023.1265571 | https://pmc.ncbi.nlm.nih.gov/articles/PMC10652795/
source_locator
Reviewed reference lines 61-61; exact primary location described in quoted passage where extracted.
Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026) · lines 61–61
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse BV2 signaling time-course. · source_derived_draft · unverified_draft
**AKT and Nrf2 involvement does not identify the binding target.** BV2 experiments recorded increased AKT phosphorylation and nuclear Nrf2. MK2206 pretreatment attenuated Nrf2 activation and partially reversed redox/nitrite responses. A reagent labeled RA also attenuated the Nrf2 response; its identity and selectivity are not independently resolved here, so no vitamin-A or retinoic-acid interaction is created from that abbreviation. Pharmacological perturbation supports pathway involvement while leaving the initiating target and off-target alternatives open. [Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced in vitro and in vivo model.](https://pubmed.ncbi.nlm.nih.gov/38026972/)
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Mouse BV2 nuclear Nrf2 accumulation